

29 September 2011

## **Proximagen Group plc**

### **Proximagen Group plc appoints Singer Capital Markets Limited as Adviser**

London, UK, 29 September 2011 - Proximagen Group plc (AIM: PRX), the rapidly growing company with a focus on the treatment of disorders of the central nervous system, announces the appointment of Singer Capital Markets Limited as its Nominated Adviser and Broker with immediate effect.

#### **Enquiries**

##### **Proximagen Group plc**

Kenneth Mulvany, Chief Executive Officer  
James Hunter, Finance Director

Tel: +44 (0)20 7400 7700

##### **Singer Capital Markets Limited**

Shaun Dobson  
Claes Spång

Tel: +44 (0)20 3205 7500

#### **M: Communications**

Peter Laing, Emma Thompson, Mary Clark

Tel: +44 (0)20 7920 2330

#### **About Proximagen**

Proximagen Group plc (AIM:PRX) is focused on the development and commercialisation of novel therapeutics primarily for diseases of the central nervous system. The Company is developing a broad pipeline of drug candidate programmes and has plans for substantial future growth through a strategy of acquisition and consolidation of innovative drug candidate programmes in its core disease areas. Proximagen believes that significant value creation opportunities can arise by building critical mass, reducing the cost base, and focusing resources on a more promising pipeline where tough decisions will be taken to discontinue weak programmes.

Proximagen strives for true scientific innovations that break new ground in treatment. Using this standard as a development benchmark makes things more challenging, but demonstrates the Company's commitment to pursuing only those opportunities that improve upon current therapies in meaningful ways and represent the best chance of generating significant commercial value. For more information, please visit the Company's website at [www.proximagen.com](http://www.proximagen.com).